Skip to main content
Premium Trial:

Request an Annual Quote

Digene Signs Deal with Quest for Routine HPV DNA Testing

NEW YORK, Jan. 27 (GenomeWeb News) - Quest Diagnostics has agreed to market Digene's DNA-based test for human papillomavirus (HPV), Digene said today.

Under the three-year agreement, Quest will offer physicians Digene's HPV test for routine cervical cancer screening in conjunction with the Pap test.

Quest previously provided the test to physicians only for follow-up evaluation of ambiguous Pap test results. Digene's HPV test was approved in March 2003 for primary cervical cancer screening, in conjunction with a Pap test, in women age 30 and over.

The American College of Obstetricians and Gynecologists, the American Cancer Society, and the Association of Reproductive Health Professionals each have updated their screening guidelines to include HPV DNA testing as part of routine cervical cancer screening for women age 30 and older, Digene said.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.